Physician
Oncology
Dr. John J. Nemunaitis, MD
|
|
Give Review
John Nemunaitis is an expert in the field of Oncology. He went to Case Western Reserve University School of Medicine. Doctor John J. Nemunaitis, MD is a published physician as well. He has 33 publications published. The latest was: The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma. Dr. John J. Nemunaitis accepts all Medicare patients.
Publications
- The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma.
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
- Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
- Liposomal insulin promoter-thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice.
- Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cel...
- Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
- Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine.
- A Phase I Trial of Oral Ridaforolimus (AP23573; MK-8669) in Combination with Bevacizumab for Patients with Advanced Cancers.
- Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors.
- Immune response and survival of refractory cancer patients who received TGF-?2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.
- RNA interference and personalized cancer therapy.
- Cancer targeting vaccines: Surrogate measures of activity.
- Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
- Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application.
- Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer.
- MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma.
- Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.
- Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastati...
- Synthetic vs. natural/biodegradable polymers for delivery of shRNA-based cancer therapies.
- Gene immunotherapy for non-small cell lung cancer.
- Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung can...
- Compassionate approval process for experimental gene-based products.
- Are vaccines making a comeback in non-small-cell lung cancer?
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
- Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metas...
- Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.
- Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
- Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secret...
Doctors Specialties
- Internal Medicine
- Oncology
Accepted Insurances
Education
-
University of Washington -
Boston University Medical Center -
Case Western Reserve University School of Medicine
Hospital
-
Medical City Dallas Hospital
Drug Facts
| NPI NUMBER | 1164464269 | |
| NPPES Provider LastName | NEMUNAITIS | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 752462003 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 107.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164464269 |
| Last Name Of The Provider | NEMUNAITIS |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Chelsea C. Talmadge, MD |
|
|
Dr. Maleka S. Khambaty, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yu-Lin Chung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristen H. Lampe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert G. Mennel, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Estil A. VanCe III, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Atisha P. Manhas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald Kerr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia R. Osborne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace J. Walton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary N. Gross, MD
This Doctor is OpenDoctor Recommended.
|